EP3851108C0 - Médicament à base de borate et utilisation associée - Google Patents
Médicament à base de borate et utilisation associéeInfo
- Publication number
- EP3851108C0 EP3851108C0 EP19860839.0A EP19860839A EP3851108C0 EP 3851108 C0 EP3851108 C0 EP 3851108C0 EP 19860839 A EP19860839 A EP 19860839A EP 3851108 C0 EP3851108 C0 EP 3851108C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- borate
- based drug
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811074536 | 2018-09-14 | ||
PCT/CN2019/104487 WO2020052488A1 (fr) | 2018-09-14 | 2019-09-05 | Médicament à base de borate et utilisation associée |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3851108A1 EP3851108A1 (fr) | 2021-07-21 |
EP3851108A4 EP3851108A4 (fr) | 2022-06-01 |
EP3851108B1 EP3851108B1 (fr) | 2023-08-09 |
EP3851108C0 true EP3851108C0 (fr) | 2023-08-09 |
Family
ID=69777291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860839.0A Active EP3851108B1 (fr) | 2018-09-14 | 2019-09-05 | Médicament à base de borate et utilisation associée |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210332069A1 (fr) |
EP (1) | EP3851108B1 (fr) |
JP (1) | JP7152078B2 (fr) |
KR (1) | KR102542264B1 (fr) |
CN (2) | CN110903310B (fr) |
WO (1) | WO2020052488A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019020099A1 (fr) * | 2017-07-28 | 2019-01-31 | 成都地奥九泓制药厂 | Composé de borate et procédé de synthèse et utilisations de ce composé |
CN110041353A (zh) * | 2018-01-16 | 2019-07-23 | 成都译山生物科技有限公司 | 一种新的硼酸水杨酸酯类衍生物及其药物组合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009020448A1 (fr) | 2007-08-06 | 2009-02-12 | Millennium Pharmaceuticals, Inc. | Inhibiteurs de protéasomes |
MX349769B (es) * | 2008-06-17 | 2017-08-11 | Millennium Pharm Inc | Compuestos de éster boronato y composiciones farmacéuticas de los mismos. |
CN102946879B (zh) * | 2010-04-19 | 2015-04-22 | 尼基制药公司 | 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用 |
MA41555A (fr) | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
CN106496259A (zh) * | 2015-09-08 | 2017-03-15 | 成都贝斯凯瑞生物科技有限公司 | 一种含硼中间体及其在医药工业中的应用 |
CN107400142B (zh) * | 2016-05-19 | 2019-11-19 | 成都奥璟生物科技有限公司 | 一种硼酸和硼酸酯类化合物及其应用 |
CN108440583B (zh) * | 2017-01-23 | 2020-12-04 | 成都奥璟生物科技有限公司 | 一种新的硼酸衍生物及其药物组合物 |
WO2019020099A1 (fr) * | 2017-07-28 | 2019-01-31 | 成都地奥九泓制药厂 | Composé de borate et procédé de synthèse et utilisations de ce composé |
CN110041353A (zh) * | 2018-01-16 | 2019-07-23 | 成都译山生物科技有限公司 | 一种新的硼酸水杨酸酯类衍生物及其药物组合物 |
-
2019
- 2019-09-03 CN CN201910829227.XA patent/CN110903310B/zh active Active
- 2019-09-03 CN CN202211129607.0A patent/CN115403603A/zh active Pending
- 2019-09-05 EP EP19860839.0A patent/EP3851108B1/fr active Active
- 2019-09-05 US US17/273,964 patent/US20210332069A1/en active Pending
- 2019-09-05 JP JP2021538880A patent/JP7152078B2/ja active Active
- 2019-09-05 KR KR1020217007521A patent/KR102542264B1/ko active IP Right Grant
- 2019-09-05 WO PCT/CN2019/104487 patent/WO2020052488A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR102542264B1 (ko) | 2023-06-13 |
EP3851108A4 (fr) | 2022-06-01 |
EP3851108B1 (fr) | 2023-08-09 |
US20210332069A1 (en) | 2021-10-28 |
JP2022500502A (ja) | 2022-01-04 |
JP7152078B2 (ja) | 2022-10-12 |
KR20210046025A (ko) | 2021-04-27 |
CN110903310B (zh) | 2022-11-22 |
CN115403603A (zh) | 2022-11-29 |
WO2020052488A1 (fr) | 2020-03-19 |
CN110903310A (zh) | 2020-03-24 |
EP3851108A1 (fr) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284835A (en) | Pharmaceutical combination containing TNO155 and ribociclib | |
IL290745A (en) | A pyrimidine compound and its pharmaceutical use | |
EP3434285A4 (fr) | Composition pharmaceutique et ses utilisations | |
IL273339A (en) | Griseofulbin compound and its medical use | |
IL282350A (en) | Bernani-RGMC inhibitors and their use | |
EP3668838A4 (fr) | Lieurs au tétramaléimide et utilisation de ces derniers | |
GB201715194D0 (en) | Compounds and their therapeutic use | |
EP3741748A4 (fr) | Composé et utilisation correspondante en médecine | |
EP3773654C0 (fr) | Compositions médicamenteuses polypharmaceutiques et méthodes associées | |
IL280644A (en) | Magnesium serine compound and its use | |
IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
IL282527A (en) | 5-Azaindazole history and their use | |
IL276311A (en) | Methyllactam ring compound and its pharmaceutical use | |
IL273713A (en) | Drug administration systems and related methods | |
EP3735277C0 (fr) | Matériaux et dispositifs médicaux | |
EP3851108C0 (fr) | Médicament à base de borate et utilisation associée | |
IL282526A (en) | 5-Azaindazole history and their use | |
IL277749A (en) | Palladianolide compounds and their use | |
IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
GB201802122D0 (en) | Product and use | |
EP4069233A4 (fr) | Association pharmaceutique et son utilisation | |
ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
EP3718543A4 (fr) | Composition pharmaceutique et son utilisation | |
EP3597640A4 (fr) | Nouveau composé de benzimidazolone et son utilisation pharmaceutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210309 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602019034834 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031690000 Ipc: C07F0005020000 Ref country code: DE Ref legal event code: R079 Ipc: C07F0005020000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220503 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/02 20060101ALI20220427BHEP Ipc: A61P 35/00 20060101ALI20220427BHEP Ipc: A61K 31/69 20060101ALI20220427BHEP Ipc: C07F 5/02 20060101AFI20220427BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230324 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019034834 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20230809 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230814 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 5 Effective date: 20231031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231110 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231123 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231109 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231209 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231110 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20231221 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230809 |